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Abstract
In the search for the most efficacious antisense oligonucleotides (AOs) aimed at inducing SMN2 exon 7 inclusion,
we systematically assessed three AOs, PMO25 (- 10, - 34), PMO18 (- 10, - 27), and PMO20 (- 10, - 29), com-
plementary to the SMN2 intron 7 splicing silencer (ISS-N1). PMO25 was the most efficacious in augmenting exon
7 inclusion in vitro in spinal muscular atrophy (SMA) patient fibroblasts and in vitro splicing assays. PMO25 and
PMO18 were compared further in a mouse model of severe SMA. After a single intracerebroventricular (ICV)
injection in neonatal mice, PMO25 increased the life span of severe SMA mice up to 30-fold, with average
survival greater by 3-fold compared with PMO18 at a dose of 20 lg/g and 2-fold at 40 lg/g. Exon 7 inclusion
was increased in the CNS but not in peripheral tissues. Systemic delivery of PMO25 at birth achieved a similar
outcome and produced increased exon 7 inclusion both in the CNS and peripherally. Systemic administration of
a 10-lg/g concentration of PMO25 conjugated to an octaguanidine dendrimer (VMO25) increased the life span
only 2-fold in neonatal type I SMA mice, although it prevented tail necrosis in mild SMA mice. Higher doses and
ICV injection of VMO25 were associated with toxicity. We conclude that (1) the 25-mer AO is more efficient than
the 18-mer and 20-mer in modifying SMN2 splicing in vitro; (2) it is more efficient in prolonging survival in SMA
mice; and (3) naked Morpholino oligomers are more efficient and safer than the Vivo-Morpholino and have
potential for future SMA clinical applications.
Introduction
Spinal muscular atrophy (SMA) is a recessively in-herited neuromuscular disease characterized by the se-
lective loss of spinal motor neurons and paralysis of skeletal
muscle in the trunk and limbs. The carrier frequency in the
general population is 1 in 35 and the prevalence is 1 in 6000
live births. It is the most common genetic cause of infant
mortality (Pearn, 1980; Feldkotter et al., 2002). The genetic
defect in patients with SMA is the loss of survival of motor
neuron (SMN) protein, caused in 95% of cases by homozy-
gous deletions of the survival of motor neuron 1 (SMN1) gene
and, rarely, by missense mutations (Lefebvre et al., 1995;
Feldkotter et al., 2002; Monani, 2005). A neighboring gene,
SMN2, is intact in all patients with SMA. SMN2 copy number
is polymorphic in the general population, and in SMA, there is
an inverse correlation between the number of copies of SMN2
and the severity of the disease. Patients with severe disease
carry one or two copies of SMN2, whereas patients with
milder disease carry three or more copies (McAndrew et al.,
1997; Taylor et al., 1998; Feldkotter et al., 2002). The SMN2
gene cannot fully compensate for the loss of the SMN1 gene,
as only 10% of its transcripts correctly splice exon 7, whereas
in SMN1 the exon is constitutive and its inclusion is essential
for the production of a functional SMN protein (Lorson et al.,
1999;Monani et al., 1999; Cartegni andKrainer, 2002; Kashima
and Manley, 2003). As SMN2 is intact in all patients with
SMA, it represents an attractive therapeutic target.
SMA is currently incurable. However, significant progress
in the development of therapeutic strategies has been
achieved. These include the following: (1) introducing the
exogenous SMN1 gene by viral vectors (Foust et al., 2010;
Passini et al., 2010; Valori et al., 2010; Dominguez et al., 2011);
(2) increasing the SMN2 transcript and SMN protein by
small-molecule drugs, such as histone deacetylase (HDAC)
inhibitors (Kernochan et al., 2005; Avila et al., 2007; Garbes
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et al., 2009; Hauke et al., 2009); (3) transplantation of motor
neuron stem cells (Corti et al., 2010); and (4) redirecting
SMN2 splicing and increasing the full-length SMN2 tran-
script by antisense oligonucleotides (AOs) (Skordis et al.,
2003; Hua et al., 2007, 2008, 2010, 2011; Baughan et al., 2009;
Williams et al., 2009; Owen et al., 2011; Passini et al., 2011;
Osman et al., 2012; Porensky et al., 2012).
The application of AOs that modify pre-messenger RNA
splicing has great potential for treating genetic diseases. The
strategy used to redirect splicing for therapeutic purpose
involves the use of AOs complementary to splice motifs or
enhancer sequences, including exonic and intronic splicing
enhancers (ESEs/ISEs) (Dominski and Kole, 1993; Dunckley
et al., 1998; Aartsma-Rus et al., 2010). One approach is to
block the binding of essential splicing factors at a specific
exon, causing it to be skipped from the mature pre-mRNA.
This strategy has been proved to be effective, and promising
results have emerged from clinical trials of AOs that promote
exon skipping in Duchenne muscular dystrophy (DMD) (van
Deutekom et al., 2007; Kinali et al., 2009; Cirak et al., 2011;
Goemans et al., 2011). In addition to enhancer sequences,
silencer sequences can also be targeted by AOs, such as ex-
onic and intronic splicing silencers (ESSs/ISSs), which are
binding sites for splicing repressors (Singh et al., 2006). These
have become important targets for the treatment of SMA.
Alternative splicing of the SMN2 gene transcript is due to
a C>T single-nucleotide substitution in exon 7 that, without
altering the amino acid encoded, disrupts an ESE in that
exon and causes it to be excluded from the mature SMN2
transcript during splicing (Cartegni and Krainer, 2002). Two
strategies have emerged for stimulating the inclusion of exon
7: (1) the use of AOs to block silencer motifs (ESSs/ISSs) or
(2) the use of bifunctional AOs to provide trans-acting ESEs
in exon 7. The bifunctional AOs were designed with one
domain that was intended to anneal to the target exon and a
second (tail) domain that contained sequences (i.e., the GGA
motif) to which activator proteins, such as the serine/argi-
nine (SR) proteins, would bind. We previously demonstrated
that one such AO stimulated the splicing of SMN2 exon 7 in
nuclear extracts of a cell-free model and that it stimulated
both splicing and SMN protein expression in fibroblasts
derived from patients with SMA. This method was termed
‘‘targeted oligonucleotide enhancers of splicing’’ (TOES)
(Skordis et al., 2003; Owen et al., 2011). A similar strategy,
exon-specific silencing enhancement by small chimeric ef-
fectors (ESSENCE), which comprises a minimal synthetic RS
domain to emulate the function of SR proteins, has also
shown efficacy in redirecting exon 7 spicing in vitro (Cartegni
and Krainer, 2003).
In the SMN2 gene, a few regulatory elements have been
shown to modulate the alternative splicing of exon 7.
These include element 1 in intron 6, an SF2/ASF (alternative
splicing factor/splicing factor-2) or hnRNP (heterogeneous
nuclear ribonucleoprotein) A1-binding site in exon 7 (the site
containing the C >T substitution), the Tra2-b1-binding site in
exon 7, the 3¢ cluster at the 3¢ end of exon 7, the splicing
silencer N1 in intron 7 (ISS-N1), and hnRNP A1-binding sites
in intron 7 (Fig. 1) (Hofmann et al., 2000; Lim and Hertel,
2001; Cartegni and Krainer, 2002; Miyajima et al., 2002;
Kashima and Manley, 2003; Singh et al., 2004, 2006; Kashima
et al., 2007). Some AOs complementary to these regulatory
sites, including conventional and bifunctional AOs, have
been designed and validated in vitro and in vivo, as shown in
Fig. 1. Among them, AOs targeting the ISS-N1 element in
intron 7 have been intensively investigated and found to be
more efficacious than AOs targeting other elements when
evaluated in various SMA mouse models (Baughan et al.,
2009; Williams et al., 2009; Hua et al., 2010, 2011; Passini et al.,
2011; Porensky et al., 2012).
AOs are designed to bind to specific nucleotide se-
quences by Watson–Crick base paring. This reduces the risk
of off-target side effects when compared with small-molecule
drugs. The efficiency of a splice-switching AO depends on
many factors: the particular sequence motifs targeted, their
length, base composition and the backbone chemical modi-
fication used (Harding et al., 2007; Owen et al., 2011). In this
study, we have investigated the efficacy of three Morpholino
AOs of various lengths complementary to ISS-N1. The
in vitro efficacy was validated in an in vitro splicing assay
and in cultured SMA patient fibroblasts. The in vivo valida-
tion was conducted in a standard SMA mouse model that
produces both mice with severe type I SMA and mice
with mild SMA (Hsieh-Li et al., 2000; Hua et al., 2010, 2011).
Single intracerebroventricular (ICV) injections of phosphoro-
amidate morpholino oligomers (PMOs) were administered
to neonatal SMA mice. Systemic delivery in neonatal SMA
mice was also investigated to exploit the early incomplete
closure of the blood–brain barrier (BBB) and to determine
the efficacy of the combined targeting of both the pe-
ripheral tissues and motor neurons. Last, we investigated
the outcomes in transgenic SMA mice of adding an octa-
guanidine dendrimer to the PMO backbone. Our com-
prehensive analyses identified a promising AO sequence
that should be considered in future experimental studies
for SMA.
Materials and Methods
SMA mouse model with human SMN2 transgene
All mouse experiments were performed according to
protocols approved by University College London (London,
UK) Biological Services and U.K. Home Office under the
Animals (Scientific Procedures) Act 1986. The initial breeding
strain of the SMA transgenic mice, FVB.Cg-Tg(SMN2)2Hung
Smn1tm1Hung/J, originally created by Hsieh-Li and colleagues
(2000), was purchased from Jackson Laboratory (TJL005058;
Jackson Laboratory, Bar Harbor, ME). Various breeding
schemes were followed as previously described (Gogliotti
et al., 2009).
FIG. 1. Schematic representation of SMN2 exon 7 splicing
regulatory elements. The functional elements regulating exon
7 splicing in SMN2 are depicted along the top. Antisense
oligonucleotides (AOs) targeting these regulatory elements
are listed at the bottom, including bifunctional AOs (gray
ovals) and conventional AOs (open rectangles).
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Morpholino antisense oligonucleotides
All Morpholinos and the Vivo-Morpholino were synthe-
sized and purified by Gene Tools (Philomath, OR). They
were dissolved to standard concentrations and stored ac-
cording to the manufacturer’s instructions.
Animal procedures
Newborn SMA mice on postnatal day (PND) 0 were
cryoanesthetized, followed by either ICV injections or facial
vein injections. Injections were performed with a glass capil-
lary (10ll) with a fine tip. For ICV injections, the glass capil-
lary was inserted to an approximate depth of 1mm, the
injection site being 1mm lateral and before the intersection of
the coronal and sagittal cranial sutures (Passini et al., 2011;
Porensky et al., 2012). Intravenous injections in newborn mice
were performed via the facial vein on PND0 with the aid of a
microscope. Intravenous injections in adult mice were per-
formed via the tail vein. Other systemic deliveries used in this
study included subcutaneous and intraperitoneal injections,
using protocols in accordance with the Laboratory Animal
Science Association (LASA) guidelines (www.lasa.co.uk).
In vitro splicing assay
Radiolabeled SMN2 transcript, prepared as described pre-
viously (Skordis et al., 2003; Owen et al., 2011), was annealed
in silanized tubes to various concentrations of Morpholinos
(PMO18, PMO20, and PMO25) at 30C for 10min in 5mM
Tris, 0.5mM EDTA, pH 8. Splicing reactions were done as
described previously (Skordis et al., 2003; Owen et al., 2011).
Quantification of pre-mRNA and both mRNA products was
done with Optiquant software (PerkinElmer, Waltham, MA),
and intensities were adjusted to account for the number of
radioactive guanosines in each molecular species.
Transfection of SMA fibroblasts
Skin fibroblast cells, derived from a patient with type III
SMA who has a homozygous deletion of the SMN1 gene and
three copies of the SMN2 gene, were cultured as previously
described (Owen et al., 2011). Cells were plated into 30-mm
diameter plates at a concentration of*2 · 105 cells per plate,
which gave 90% confluence by the next day. PMOs were
complexed with Lipofectamine 2000 (Invitrogen/Life Tech-
nologies, Carlsbad, CA) in Opti-MEM (Invitrogen/Life
Technologies) according to the manufacturer’s instructions,
and added to cells. Cells were harvested 48 hr after trans-
fection for RNA and protein extraction. All experiments were
repeated at least three times for each PMO.
Reverse transcription PCR and real-time
RT-PCR analyses
Total RNA was extracted from cultured fibroblasts or
homogenized mouse tissues, using an RNeasy kit (Qiagen,
Chatsworth, CA). Total RNA (500 ng) was used for first-
strand cDNA synthesis, using a SuperScript III reverse
transcription kit (Invitrogen/Life Technologies). Human
SMN-specific primers (forward, 5¢-CTC CCA TAT GTC CAG
ATT CTC TT-3¢; reverse, 5¢-CTA CAA CAC CCT TCT CAC
AG-3¢) were used to amplify SMN2 and gave two PCR
products, the full-length SMN2 (505 bp) and D7 SMN2
(451 bp). Quantitative real-time PCR was done with a MESA
Blue qPCR kit (Eurogentec, Seraing, Belgium). Samples were
incubated in a 25-ll reaction mix according to the manu-
facturer’s instructions. The same cDNA products as de-
scribed previously were used as templates for real-time PCR.
Human-specific full-length SMN2 primers (forward, 5¢-ATA
CTG GCT ATT ATA TGG GTT TT-3¢; reverse, 5¢-TCC AGA
TCT GTC TGA TCG TTT C-3¢ [133 bp]) and human-specific
SMN D7 primers [forward, 5¢-TGG ACC ACC AAT AAT
TCC CC-3¢; reverse, 5¢-ATG CCA GCA TTT CCA TAT AAT
AGC C-3¢ [125 bp]) were used. Quantitative real-time PCR
was performed with an Applied Biosystems/Life Technolo-
gies (Carlsbad, CA) fast 7500 real-time PCR system as de-
scribed previously (Owen et al., 2011). The program includes
activation at 95C for 5min, 40 cycles of 95C for 3 sec, and
60C for 1min. Quantification was based on concurrent
standard curves produced from serial dilutions of cDNA
from the fibroblasts of an untreated patient with SMA. The
cycle at which the amount of fluorescence was above the
threshold (Ct) was detected. The ratios of full-length SMN2
to D7 SMN2 of the treated samples were normalized, taking
the ratio of the untreated sample, or saline control of mouse
tissues, as 1.0.
Western blotting
Fibroblasts or mouse brain was lysed in buffer containing
75mM Tris-HCl (pH 6.8) and 0.25% sodium dodecyl sulfate
(SDS) supplemented with protease inhibitor cocktail (Roche
Diagnostics, Indianapolis, IN). Protein concentration was
analyzed with a bicinchoninic acid (BCA) kit (Pierce Bio-
technology/Thermo Fisher Scientific, Rockford, IL) accord-
ing to the manufacturer’s instructions. Five micrograms of
total protein extracted from fibroblasts, or 50lg of total
protein extracted from mouse brain, was loaded into 10%
NuPAGE Bis-Tris precast gels (Invitrogen/Life Technolo-
gies). SMN protein was blotted as previously described
(Owen et al., 2011). The primary anti-SMN antibody used in
SMA fibroblasts was BD Transduction Laboratories mouse
anti-SMN monoclonal antibody (diluted 1:2000; BD Bios-
ciences, San Jose, CA); the human-specific SMN antibody
used in mouse brain was mouse anti-SMN 4F11 monoclonal
antibody (diluted 1:1000; from C. Lorson, University of
Missouri, Columbia, MO) (Mattis et al., 2008). b-Tubulin
was used as protein loading control and was detected
with mouse anti-b-tubulin monoclonal antibody (1:5000;
Sigma-Aldrich, St. Louis, MO). Membranes were blocked
overnight in 10% semiskimmed milk in phosphate-buffered
saline (PBS)–0.1% Tween (PBST). After incubation for 1 hr at
room temperature with various primary antibodies, mem-
branes were washed in PBST, followed by administration
of secondary horseradish peroxidase (HRP)-conjugated anti-
mouse IgG antibody (GE Healthcare Life Sciences, Piscat-
away, NJ) at a dilution of 1:50,000 in PBST. Blots were
developed with an enhanced chemiluminescence detection
kit (GE Healthcare Life Sciences). Quantification of band
intensity was analyzed with ImageJ software (Rasband,
1997–2012).
Statistical analysis
Student t tests were used to determine statistical signifi-
cance. Data are displayed as means – standard error
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(means – SE). Kaplan–Meier survival curves were generated
to analyze the survival data, followed by a log-rank test for
statistical significance. GraphPad Prism 5.0 software
(GraphPad, San Diego, CA) was used for statistical analysis
and graph design.
Results
ISS-N1 is an intronic splicing silencer of 15 nucleotides
located in the 5¢ region of intron 7 in SMN1 and SMN2
genes (Singh et al., 2006). It has been shown previously that
AOs complementary to ISS-N1 from intron nucleotide 10
(-10) onward produced efficient exon 7 inclusion and res-
cued SMA transgenic mice (Hua et al., 2010, 2011; Passini
et al., 2011; Porensky et al., 2012). These AOs comprised an
18-mer based on 2¢-O-methoxyethyl chemistry and a 20-mer
phosphorodiamidate morpholino antisense oligonucleotide
(PMO). To test whether length was a factor influencing
their splice-switching ability, Morpholino AOs comple-
mentary to 18 (- 10, - 27; PMO18), 20 (- 10, - 29; PMO20),
and 25 (- 10, - 34; PMO25) bases of ISS-N1 were tested,
all of which extended from nucleotide 10 of the intron 7
(Fig. 2).
Effects of PMOs on SMN2 alternative splicing
in cell-free in vitro splicing assay
An SMN2 cell-free in vitro splicing assay was used to
compare the efficiencies of PMO18, PMO20, and PMO25. The
PMOs were incubated with the pre-mRNA substrate and
then mixed with a splicing reaction mixture (Skordis et al.,
2003; Owen et al., 2011). All three PMOs gave rise to sub-
stantial exon 7 inclusion at concentrations of 250 and 500 nM
(Fig. 3A). This demonstrates that their primary effect is di-
rectly on pre-mRNA splicing rather than on other processes,
such as RNA stability. When comparing the intensities of the
bands representing exon 7 inclusion with the exon 7 exclu-
sion product, PMO25 was more efficient at inducing exon 7
inclusion than PMO18 and PMO20 at 250 nM ( p < 0.0001;
Fig. 3B).
Comparative analysis of PMO18, PMO20, and PMO25
in SMA patient fibroblasts
PMO18, PMO20, and PMO25 were transfected into SMA
type III patient fibroblasts at concentrations of 100 and 500nM.
Reverse transcription-PCR revealed clear differences in
the splicing patterns of cells treated with the three PMOs
(Fig. 3C). Exon 7 inclusion in PMO-treated fibroblasts was
further quantified by measuring the ratio of full-length
SMN2 transcript to D7 SMN2 transcript by quantitative
real-time PCR (Owen et al., 2011). At 100 nM, there was no
difference between PMO18 and PMO20, but a significant
increase in exon 7 inclusion was identified in PMO25-treated
compared with PMO18- and PMO20-treated fibroblasts
( p= 0.0033 and p = 0.0022, respectively). At 500 nM, PMO25-
treated fibroblasts showed the strongest exon 7 inclusion
compared with both PMO18 and PMO20 ( p < 0.0001 and
p = 0.0003, respectively). The exon 7 inclusion induced by
PMO25 was 2.6- and 1.8-fold greater than that induced with
PMOs 18 and 20, respectively (Fig. 3D).
The restoration of SMN protein consequent to the in-
creased exon 7 inclusion in transfected fibroblasts was ex-
amined by Western blotting. PMOs 18, 20, and 25 were
transfected into SMA type III patient fibroblasts at concen-
trations of 500 and 1000 nM. At both concentrations, PMO25
gave rise to significantly more SMN protein than did PMOs
18 and 20 ( p< 0.0001 and p= 0.0007 at 500 nM, p= 0.0015 and
p = 0.0013 at 1000 nM, respectively), resulting in 2- and 1.6-
fold, respectively, higher levels of protein expression (Fig. 3E
and F).
SMN2 exon 7 inclusion and SMN protein expression
induced by PMOs in SMA mice
Because PMO25 was significantly more effective than
PMO18 and PMO20 in correcting SMN2 exon 7 splicing
in vitro, whereas PMO18 and PMO20 showed a similar effect,
the efficacy of PMO25 was then compared with PMO18 in an
SMA mouse model.
Litters born from the breeding pairs of mice with geno-
type (SMN2)2
+/+ ; smn–/– crossed with the genotype smn+/–
have 50% wild-type ‘‘heterozygous’’ progeny with geno-
type (SMN2)2
+/–; smn +/– and 50% severe type I SMA
progeny with genotype (SMN2)2
+/–; smn–/–. Newborn
(PND0) mice, of both genotypes, were given a single ICV
injection of PMO18 or PMO25 at 20 lg/g. Injected mice
were genotyped to identify heterozygous and type I SMA
mice. The heterozygotes [(SMN2)2
+/–; smn +/–] were used in
the analysis of SMN2 exon 7 inclusion and SMN protein by
using human SMN2-specific primers and a human-specific
SMN antibody. Brain and spinal cord tissues were collected
at intervals of 10 days, starting from 10 days postinjection
until 40 days. The ratio of human full-length SMN2 tran-
script to human D7 SMN2 transcript was measured by
quantitative real-time PCR with primers specific for human
SMN2 transcripts (Fig. 4A). Ten days after PMO adminis-
tration, RNA isolated from brain and spinal cord showed
prominent exon 7 inclusion in mice treated with both
PMO18 and PMO25 (Fig. 4A). No significant difference in
exon 7 inclusion was observed between the two PMOs at this
time point. Twenty days after injection, exon 7 inclusion
remained at high levels in brain and spinal cord from
PMO25-treated mice, but it was dramatically reduced in
PMO18-treated mice (Fig. 4A). Analyzed by quantitative
real-time PCR, the ratio of human full-length SMN2 tran-
script to human D7 SMN2 transcript induced by PMO25 was
more than 2-fold greater than that induced by PMO18 in
both brain ( p= 0.0297) and spinal cord ( p= 0.0055; Fig. 4B).
The effect on exon 7 inclusion in peripheral tissues was
FIG. 2. Diagrammatic representation of the positions of
AOs targeting the ISS-N1 region. The sequence of exon 7 is
shown in upper case and that of intron 7 in lower case. The
sequence of ISS-N1 and the annealing sites for the 18-mer
ASO-10–27, 20-mer HSMNEx7D, and 25-mer PMO25 are
highlighted. Note: In the Morpholinos the uridine (U) is re-
placed by thymine (T).
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also measured after ICV injection in PMO18- and PMO25-
treated heterozygous [(SMN2)2
+/–; smn +/–] mice. Tibialis
anterior (TA) muscle, heart, liver, and kidney were collected
10 days after injection (PND10). Real-time PCR showed that
ICV injection produced no change in exon 7 inclusion in
these peripheral tissues, either in PMO18- or PMO25-treated
mice (data not shown).
To assess the persistence of the effect from a single ad-
ministration of PMO25 (20lg/g) in mouse brain and spinal
cord, SMN2 exon 7 inclusion was measured at 10-day in-
tervals until PND40. Three treated mice per time point were
collected. The ratio of human full-length SMN2 transcript to
human D7 SMN2 transcript declined on PND30 and nearly
reached baseline levels on PND40 (Fig. 4C).
The dose was increased to 40lg/g, again administered in
a single ICV injection to newborn mice on PND0. Twenty
days after injection, the ratio of human full-length SMN2
transcript to human D7 SMN2 transcript induced by PMO25
was about 2-fold greater than that induced by PMO18 in
brain ( p= 0.0033), and 1.6-fold in spinal cord ( p = 0.0496; Fig.
4D).
The level of human SMN protein expression after the
administration of PMOs was measured by Western blotting
with a human-specific SMN antibody (Mattis et al., 2008). A
significant increase in the level of expression was detected 10
days after PMO administration in the brains of mice treated
with PMO18 and PMO25 at 20 lg/g. Expression was mark-
edly higher in PMO25-treated mice than in PMO18-treated
mice ( p= 0.0186; Fig. 4E and F).
The survival of severe SMA mice treated by single ICV
injection of PMO25 or PMO18
Survival curve studies were performed on type I SMA
mice [(SMN2)2
+ /–; smn–/–] given a single ICV injection on
PND0 of either PMO25 (20 lg/g, n = 9 or 40 lg/g, n = 8) or
PMO18 (20 lg/g, n = 6 or 40 lg/g, n = 6), or saline control
(n = 6). Mice were weighed daily and assessed for tail and
ear necrosis and mortality. Mice injected with saline sur-
vived for an average of 9.5 days. However, mice treated
with PMO18 (20 lg/g) survived for an average of 12 days,
with a maximal life span of 25 days. Mice treated with
PMO25 survived for an average of more than 43 days, the
longest survival being 185 days ( p = 0.01 for the comparison
of PMO25 and PMO18; Fig. 5A). Increasing the single ICV
injection on PND0 to 40 lg/g further improved the average
survival to 32 days with PMO18 and 85.5 days with
PMO25, with the longest survival being 298 days (Fig. 5B).
The survival advantage was significant for both PMO18-
and PMO25-treated groups when compared with saline
control mice ( p < 0.0001). There was also a significant dif-
ference between the PMO25 and PMO18 groups, in favor of
PMO25 ( p = 0.0111).
In addition to the prolongation of life span, a single ICV
injection of PMOs into newborn type I mice had a significant
effect on body weight (Fig. 5C and D). At 40lg/g, mice
treated with both PMO18 and PMO25 showed a steady in-
crease in weight, which was similar to the gain in body
mass induced by PMO25 at 20lg/g. The low weight gain
FIG. 3. PMO25 promotes exon 7 inclusion in vitro. (A) Cell-free in vitro splicing assay using radiolabeled SMN2 transcripts
combined with PMO18, PMO20, or PMO25 at concentrations between 0 and 500 nM. (B) Graph showing ratio of SMN2 exon
7 inclusion to exclusion with increasing concentrations of PMOs. The relative ratio labeled on the y axis indicates that the
readings have been normalized against the reading obtained for the no-PMO (0 nM) sample. (C) A representative reverse
transcription-PCR image shows the effect of PMOs on SMN2 exon 7 inclusion in cultured SMA fibroblasts. Cells were treated
at 100 and 500 nM in each PMO group. (D) Quantitative real-time PCR assay of the relative expression of full-length SMN2
transcript against the D7 SMN2 transcript in PMO-treated SMA fibroblasts. (E) Western blotting of SMN protein in PMO-
treated SMA fibroblasts. (F) Semiquantitative analysis of SMN protein expression normalized to tubulin. *p < 0.05; **p< 0.01;
***p < 0.001.
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observed in mice given PMO18 at 20lg/g might be related
to their poor survival. All treated type I mice had short tails,
with tail necrosis commencing between 60 and 80 days of
age, leading to complete tail loss between 80 and 100 days.
Ear necrosis started between 40 and 50 days. No difference in
tail and ear necrosis was observed between PMO18- and
PMO25-treated type I mice.
Efficacies of systemically delivered PMOs in type I
SMA mice
The efficacies of delivery routes other than ICV injection
were assessed in type I SMA mice. For the assessment of a
single systemic application, type I mice were injected with
PMO25 (40lg/g) intravenously, via the facial vein, on PND0
(n = 8); for repeat systemic deliveries, intravenous injection
on PND0 was followed by a second intraperitoneal or sub-
cutaneous injection of PMO25 (40 lg/g) on PND3 (n= 6).
Mice were then weighed daily and assessed for survival. The
average survival of the single intravenous-injected group has
not yet been determined, as five of eight mice are still alive at
the time of submission of this manuscript (beyond 230 days).
Nevertheless, the predicted average survival of the single
intravenous-injected group, beyond 230 days, is longer than
the average survival of the repeat systemic group, which was
93.5 days. This suggests that repeated injections do not
confer an advantage to severe SMA mice. The average sur-
vival in the repeated systemically injected group is similar to
the average 85-day survival of mice given a single 40-lg/g
ICV injection (Fig. 6A).
The three different delivery routes showed a similar as-
cending trend of body weight gain over times. At about
50 days of age, the ICV-treated type I SMA mice (n= 3)
increased body weight to 77% of control heterozygotes
[(SMN2)2
+/–; smn +/–, n= 5]; the single intravenous-injected
type I SMA mice (n = 6) gained body weight to 80% of het-
erozygous controls; and the repeat systemically injected type
I SMA mice (n= 3) gained 70% of the body weight of het-
erozygous controls. At 140 days of age, there were three type
I mice still alive in the ICV 40-lg/g treated group, with an
average body weight of 19.3 g, which was equivalent to 83%
of the average body weight of heterozygous controls. The
FIG. 4. Effects of PMO18 and PMO25 on exon 7 inclusion and human SMN protein expression in SMA transgenic mice.
(A) Newborn SMA transgenic mice that carried two copies of the human SMN2 gene were administered, by in-
tracerebroventricular (ICV) injection, PMO18 or PMO25 at 20 lg/g on postnatal day (PND) 01. Exon 7 inclusion in brain and
spinal cord was analyzed by reverse transcription-PCR 10 and 20 days postinjection. Representative RT-PCR gel images are
displayed. (B) Quantitative real-time PCR analyses of exon 7 inclusion in brain and spinal cord, 10 and 20 days after a single
ICV injection of saline or either PMO18 or PMO25 at 20lg/g on PND0. *p< 0.05; **p< 0.01. (C) Quantitative real-time PCR
analyses of exon 7 inclusion in brain and spinal cord, examined from PND10 to PND40 at 10-day intervals, after a single ICV
injection of PMO25 (20lg/g) on PND0. (D) Newborn SMA transgenic mice that carried two copies of the human SMN2 gene
were given PMO18 or PMO25 at 40lg/g by ICV injection on PND0. Quantitative real-time PCR analyses of exon 7 inclusion
in brain and spinal cord were performed 20 days later. *p< 0.05. (E) Western blotting of human SMN protein expressed in
brain from PMO-treated SMA transgenic mice. The expressed protein was probed by a human-specific SMN antibody in
samples extracted from mice treated by ICV injection of PMO25 or PMO18 (20lg/g) on PND0. (F) Semiquantitative analysis
of human SMN protein expression normalized to tubulin. *p< 0.05; **p< 0.01; ***p< 0.001.
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FIG. 5. Survival curves and weight gain of type I SMA mice treated with PMO18 and PMO25 by ICV injection. (A) Survival
curves of type I SMA mice treated with a single ICV injection of PMO18 or PMO25 at 20 lg/g on PND0. (B) Survival curves
of type I SMA mice treated with a single ICV injection of PMO18 or PMO25 at 40 lg/g on PND0. (C) Body weight gain up to
30 days in type I mice treated with PMOs at 20lg/g. Less weight gain was observed in PMO18-treated mice, corresponding
to their poor survival. (D) Body weight gain up to 30 days in type I mice treated with PMOs at 40lg/g. Saline-injected type I
mice and heterozygous control mice [(SMN2)2
+/–; smn +/–] were used as body weight controls.
FIG. 6. Efficacies of various delivery routes in type I SMA mice. Type I SMA mice were administered PMO25 (40 lg/g) by a
single ICV injection on PND0, or by single systemic delivery (via the facial vein) on PND0, or by repeat systemic deliveries on
PND0 (via the facial vein) and PND3 (subcutaneously or intraperitoneally). (A) Survival curves of type I SMA mice treated
with PMO25 via different delivery routes at 40lg/g. (B) Body weight gain in type I mice treated with PMO25 at 40lg/g by
single ICV, single intravenous, or repeated systemic injections. (C) Representative reverse transcription-PCR gel images show
exon 7 inclusion in CNS tissues (brain and spinal cord) and peripheral tissues (TA muscle, heart, liver, and kidney) 10 days
after the repeat systemic administration. (D) Quantitative analyses of exon 7 inclusion by real-time PCR in CNS and
peripheral tissues after systemic administrations. *p < 0.05; **p < 0.01; ***p < 0.001.
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average body weight increased to 86% of the heterozygous
controls at 160 days of age (Fig. 6B).
In addition, we examined exon 7 inclusion in the CNS and
peripheral tissues in heterozygous [(SMN2)2
+/–; smn+/–] mice
after repeat systemic deliveries. Tissues from CNS (brain and
spinal cord) and other organs (heart, TA muscle, liver, and
kidney) were collected on PND10 after PND0 (intravenous)
and PND3 (subcutaneous) systemic injections. The ratio of
full-length SMN2 to D7 SMN2 was measured by SMN2-
specific real-time PCR. Compared with the saline-treated
control, there was an approximately 2-fold increase in exon 7
inclusion in brain ( p= 0.0014) and spinal cord ( p= 0.0003) after
systemic injection of PMO25 at 40lg/g on PND0. Similar
increases were also observed in the liver ( p= 0.0129), but not
in muscle, heart, and kidney (Fig. 6C and D). This suggests
that PMO25 administered systemically to neonatal mice may
reach the CNS because of the immaturity of the BBB barrier in
very young mice. Our data imply that the correction of exon 7
inclusion in the CNS, induced by systemic PMO administra-
tion in the neonatal period, contributes in a major way to
extending the life span of type I SMA mice.
Efficacy of Vivo-Morpholino in SMA mice
To investigate whether an octaguanidine moiety can im-
prove the efficacy of the Morpholino AO in SMA mice,
PMO25 was conjugated with a dendrimeric octaguanidine
during synthesis. The product, 25-mer Vivo-Morpholino AO
(VMO25), was administered to both severe type I and mild
SMA mice.
Type I SMA mice were treated by an intravenous injection
of VMO25 (7lg/g) via the facial vein on PND0, followed by
an intraperitoneal injection of the same dose on PND3. The
average survival of VMO25-treated type I SMA mice (n= 7)
was 16 days, compared with 10 days in saline-treated type I
mice (n = 7; p= 0.0039). Increasing the dose to 10lg/g did not
improve the efficacy. The survival of VMO25-treated type I
mice was significantly lower than that of mice treated by
systemic delivery of naked PMO25 at 40lg/g, which was
93.5 days (n = 6) ( p= 0.0085; Fig. 7A).
The mild SMA mice [(SMN2)2
+/+ ; smn–/–] carry four
copies of the human SMN2 gene. These mice have a normal
life span, body weight, and fertility, but nevertheless exhibit
tail and ear necrosis (Hsieh-Li et al., 2000). The onset of tail
necrosis typically starts between 2 and 3 weeks of age,
leading to complete loss of the tail by 8 weeks. Mice were
injected with saline or VMO25 at 10 lg/g via the facial vein
on PND0. In saline-treated mice, tail necrosis started after 3
weeks, part of the tail was lost by 4 weeks, and the tail had
nearly completely disappeared by 8 weeks of age (Fig. 7B). In
contrast, the tails of mild SMA mice treated with VMO25
appeared normal at 9 months of age, although they were
FIG. 7. Efficacy of VMO25 in type I and mild SMA mice. (A) Survival curves of type I mice after systemic delivery of
VMO25 or PMO25 on PND0. (B) Tail rescue by VMO25 in mild SMA mice. The genotype of mouse 1 was (SMN2)2
+/ + ;
smn +/–, used as wild-type control; the genotype of mice 2 and 3 was (SMN2)2
+/+ ; smn–/– , that is, mild SMA mice. Single
facial vein injections of saline into mice 1 and 2, and of VMO25 (10lg/g) into mouse 3, were conducted on PND0. Images of
the mice were captured at ages of 3 weeks, 4 weeks, 8 weeks, and 9 months. Tail necrosis in mouse 2 (arrowed) had clearly
progressed with time. VMO25-treated mild SMA mouse 3 (asterisked) had a slightly shorter but normal-looking tail com-
pared with wild-type mouse 1. (C) Effect of systemically delivered VMO25 in young adult mice on exon 7 inclusion in CNS
and peripheral tissues. VMO25 (10 or 5 lg/g) was injected into young adult heterozygous SMA mice on PND21 via the tail
vein. Brain, spinal cord, skeletal muscle (TA), heart, liver, and kidney were collected 10 days after the injection. Exon 7
inclusion in these tissues was analyzed by reverse transcription-PCR and quantified by real-time PCR. Representative reverse
transcription-PCR pictures are displayed. (D) The ratio of full-length SMN2 transcript to D7 SMN2 transcript was quantified
by real-time PCR (*p < 0.05; ***p< 0.001). (E) Survival curves of type I SMA mice treated with a single ICV injection of VMO25
at 4 or 2lg/g.
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slightly short in comparison with those of wild-type mice
(Fig. 7B). Slow progress of tail necrosis started at about 10
months of age in VMO25-treated mild SMA mice. Un-
conjugated PMO25 was also tested at 20 lg/g by ICV injec-
tion into neonatal mild SMA mice. The onset of tail necrosis
started at about 8 weeks of age, significantly delayed com-
pared with 3 weeks in saline control, but still less impressive
than that of VMO25.
Because Vivo-Morpholino has shown significant efficacy
on exon skipping in skeletal and cardiac muscle in mdx mice
(Wu et al., 2009), a model of human DMD, we then examined
the target organs of VMO25 in SMA mice and its ability to
cross the BBB in adult mice. Three-week-old heterozygous
mice with the genotype of (SMN2)2
+/–; smn +/– were injected
with VMO25 at a dose of 5 or 10lg/g via the tail vein. After
10 days, tissues were collected from brain, spinal cord, TA
muscle, heart, liver, and kidney. Exon 7 inclusion was
analyzed by reverse transcription-PCR and quantified by
real-time PCR. Whereas prominent exon 7 inclusion was
observed in peripheral tissues such as skeletal muscle and
kidney, there was no evidence of inclusion in brain and
spinal cord (Fig. 7C). This observation was confirmed by
quantitative real-time PCR. Striking exon 7 inclusion was
obtained in the TA muscle and kidney, followed by liver, but
not in heart, brain, and spinal cord (Fig. 7D). Hence, the 25-
mer Vivo-Morpholino was inefficient in inducing exon 7
inclusion in the CNS after its systemic delivery in adult mice.
The administration of VMO25 by ICV injection was also
examined in newborn SMA mice. After administration of
10 lg/g, all injected pups, including both type I and het-
erozygous mice, died overnight. When the dose was reduced
to 4lg/g, half of the injected mice died overnight. We
monitored the survival and general condition of the re-
maining VMO25-injected mice. Three type I mice survived
until PND15–17. Two injected heterozygous mice lived until
PND25 and had to be culled because of severe hydroceph-
alus. After reducing the dose to 2 lg/g, no mice died on the
second day, but no significant improvement in survival was
observed in type I SMA mice. The injected type I mice died
between PND7 and PND12, with survival similar to that of
saline-treated type I SMA mice (Fig. 7E).
Discussion
Manipulating SMN2 pre-mRNA splicing by AOs to in-
duce the inclusion of exon 7 in the mature transcript, hence
increasing the amount of SMN protein, is a promising ther-
apeutic strategy for SMA. Nine AOs, including bifunctional
AOs, have been previously investigated in in vitro and in vivo
experimental systems (Fig. 1). The most impressive outcomes
in SMA transgenic mice are from two AOs binding to the
ISS-N1 in intron 7, the 18-mer ASO 10–27 (- 10, - 27) and 20-
mer HSMN2Ex7D (- 10, - 29) (Hua et al., 2011; Porensky
et al., 2012). Our aim was to refine the design of an AO
binding to ISS-N1 and explore the feasibility of obtaining an
even more potent AO, so as to reduce the frequency of re-
peated administrations in future clinical trials in patients
with SMA. For this purpose, an AO that can safely induce
sustained and pronounced full-length SMN2 expression
when applied at a low dose is required.
In this study, we conducted a systematic comparison of
the efficacies of three AOs with a Morpholino backbone, all
targeting the ISS-N1 core sequence. These had lengths of 18
(PMO18), 20 (PMO20), and 25 (PMO25) bases, respectively.
The efficiencies of the PMOs were assessed by previously
validated and widely used in vitro and in vivo assays, that is,
by in vitro cell-free splicing and measurements of exon 7
inclusion and SMN protein expression in transfected SMA
fibroblasts (Owen et al., 2011); and, more importantly, by
their efficacy in an SMA transgenic mouse model. Consistent
results were obtained in all the in vitro assays: PMO25 is
more efficient than PMO18 and PMO20 in inducing exon 7
inclusion in splicing in vitro and in SMA fibroblasts. The
superiority of PMO25 to PMO18 was further confirmed in
SMA transgenic mice after administrations in newborn type I
SMA mice.
Porensky and colleagues administered a single ICV injec-
tion of Morpholino HSMN2Ex7D AO, which is the same as
PMO20, to newborn severely affected SMND7 mice. The AO
increased survival at all doses (27, 54, and 81 lg in total),
with an increase in the average survival to 83 to 112 days,
compared with 15 days for the untreated control (Porensky
et al., 2012). This outcome is similar to our survival data
obtained from ICV or intravenous injection of PMO25 at
40lg/g. However, the experiments were conducted in a
different mouse model of SMA, SMND7 mice (SMN2+/+ ;
Smn–/–; SMND7 +/ + ), developed by Le and colleagues (2005),
which lacks mouse Smn and carries two copies of human
SMN2 and SMND7. Despite the fact that these mice display a
phenotype similar to the type I SMAmouse model used here,
which carries truncated mouse Smn lacking exon 7 and two
copies of human SMN2, developed by Hsieh-Li and col-
leagues (2000), SMND7 mice have a longer median survival
(*15 days) than the type I SMA mice (*10 days). The dif-
ference in baseline survival time between these two SMA
mouse models obviously affects survival after AO adminis-
tration.
The most common AO chemistries used at present are
2¢-O-methyl (2¢-OMe) phosphorothioate, 2¢-O-2-methoxyethyl
(MOE) phosphorothioate, and PMO. They have all been
widely used in preclinical studies and clinical trials. How-
ever, the therapeutic application of 2¢-OMe and MOE AOs is
limited by liver toxicity when using MOE AOs, and liver and
kidney toxicity when using 2¢-OMe AOs (Kling, 2010; Raal
et al., 2010; Akdim et al., 2011; Goemans et al., 2011). In con-
trast, the PMO backbone has been demonstrated to be well
tolerated with no drug-related adverse effect in two com-
pleted clinical trials in which systemic administration of a
PMO at doses up to 20 and 50mg/kg, respectively, was
done in boys with DMD (Cirak et al., 2011; and http://
investorrelations.avibio.com/phoenix.zhtml?c = 64231&p =
irol-newsArticle&ID = 1678924&highlight = ).
Preclinical studies have indicated no drug-related adverse
events in primates receiving repeated administrations of the
maximal feasible dose (320mg), or in mice receiving long-
term (>1 year) PMO at doses of 1000 lg/g (Sazani et al.,
2011). The absence of PMO toxicity in CNS was confirmed in
a study using ICV injection of the PMO20 (HSMN2Ex7D) in
neonatal SMAD7 mice, where doses as high as 405 lg
showed no evidence of toxicity (Porensky et al., 2012).
In the present study, we showed that ICV injection of
PMO18 at 40lg/g significantly increased the average sur-
vival of type I SMA mice from 10 to 43 days. A similar 20-
mer antisense sequence but with a 2¢-OMe backbone did not
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improve survival of SMND7 mice, after repeated ICV injec-
tions (Williams et al., 2009). Furthermore, a proinflammatory
effect in the brain and spinal cord was detected when the 20-
mer 2¢-OMe was administered into the CNS, in the absence
of any effect on SMN2 exon 7 inclusion (Hua et al., 2010).
Modification of the 2¢-OMe backbone to MOE chemistry, by
using ASO-10–27, only extended the life span of SMND7
mice from 15 to 26 days after ICV injection of 4 lg into
neonatal mice (Passini et al., 2011). Increasing the dose to
16 lg resulted in a dramatic death rate within 24 hr of ICV
injection (Passini et al., 2011). In contrast, a subsequent study
using systemic administration of the 18-mer MOEASO-10–27
at a high dose of 160lg/g extended the median life span of
type I SMA mice from 10 days to more than 200 days. A
possible explanation of these results might be that there is
some MOE toxicity in direct CNS administration. In that
study, although SMN2 splicing in the CNS was corrected at a
similar efficiency as in other peripheral tissues, it was con-
cluded that peripheral administration of MOE was essential
for longer survival and required for the rescue of the SMA
phenotype. On the other hand, scAAV8-SMN CNS delivery
and transgenic approaches limiting SMN expression to the
CNS or skeletal muscle suggest that rescue of SMN expression
in the CNS is essential for effective treatment of SMA in mice
(Gavrilina et al., 2008). Moreover, both the study on neonatal
ICV injection of the 20-mer Morpholino and our present study
show dramatic rescue of the SMA phenotype but no periph-
eral modulation of SMN2 splicing, in keeping with the poor
crossing of the BBB by the PMOs (Porensky et al., 2012). Our
current results and those of Porensky and colleagues show
that there is no significant difference in survival between the
delivery routes when comparing ICV with systemic Mor-
pholino administrations in neonatal SMA mice.
Novel approaches to improve systemic AO delivery have
been intensively investigated with the aim of permitting
lower doses of AOs to be used, compatible with acceptable
safety and toxicity profiles, and to facilitate the efficiency of
therapeutic AOs in target tissues. Two principal delivery
moieties have been conjugated to the uncharged PMO: short
arginine-rich cell-penetrating peptide-conjugated PMOs
(PPMOs) and nonpeptide dendrimeric octaguanidine (Vivo-
Morpholinos). These delivery moieties have been intensively
investigated in mdx mice, and showed enhanced delivery of
Morpholino and improved expression of dystrophin in
skeletal and cardiac muscle after systemic delivery (Wu et al.,
2008, 2009; Yin et al., 2008; Moulton and Jiang, 2009; Wood
et al., 2010). A Vivo-Morpholino targeting mouse dystrophin
exon 23 (Vivo-ME23) showed significantly improved efficacy
in inducing exon skipping in mdx mice without any notice-
able toxicity (Wu et al., 2009). However, the conjugation of
the octaguanidine moiety with PMO25 (VMO25) in the
present study in SMA mice gave equivocal results. VMO25
was much less effective than PMO25 in rescuing severe type I
SMA mice after systemic delivery (average survival, 16 vs.
93.5 days). In addition, the CNS toxicity on direct delivery of
VMO25 by ICV injection was noticeable. Lowering the dose
diminished the toxicity but failed to rescue the mice. These
data therefore highlight limitations of the octaguanidine
Morpholino as a potential therapy for SMA or other CNS
conditions in humans. Nevertheless, systemic delivery of
VMO25 in newborn mild SMA mice showed striking success
in rescuing tail and ear necrosis. Tail and ear necrosis is a
typical feature in SMA mice with a mild phenotype (Hsieh-Li
et al., 2000; Tsai et al., 2006), which could be reminiscent of the
digit necrosis observed in some severe cases of type I SMA in
children (Araujo et al., 2009; Rudnik-Schoneborn et al., 2010).
Although the mechanism of tail necrosis in SMA mice is still
unclear, a possibility is that it could be related to vasculopathy
induced by skeletal muscle denervation or autonomic nervous
system dysfunction (Tsai et al., 2006; Araujo et al., 2009; Hua
et al., 2010; Rudnik-Schoneborn et al., 2010). The tail rescue
observed in mild SMA mice is more impressive in VMO25-
treated than PMO25-treated mice. When comparing the target
organs, whereas both AOs showed efficacy in the brain and
spinal cord, only VMO25 showed an effect on SMN2 exon 7
inclusion in skeletal muscle. This result may indicate that
skeletal muscle or other peripheral tissues are closely involved
in the scenario of vasculopathy in SMA.
Our study has shown that the naked Morpholino is more
efficient than any of the other AOs studied, with no apparent
toxicity after both CNS and systemic administrations. There
is clear evidence that CNS restoration of SMN protein is
essential in rescuing SMA phenotypes. Although we and
others have shown that AOs can cross the BBB and exert
their action in the CNS when administered systemically at
high dose in newborn mice, it is unlikely they are capable of
BBB penetration in humans, even in infants, as the BBB is
fully developed before birth in humans. Therefore direct
CNS delivery, for example, ICV or intrathecal delivery, will
be necessary in clinical trials, unless efficient brain targeting
after systemic delivery becomes feasible. Thus, the use of an
AO with no CNS toxicity will be vital. Our data provide clear
evidence that PMO25 is superior, both in terms of potency at
low dose and in terms of longevity of action, compared with
PMO18. From a therapeutic point of view it would be pref-
erable to use AOs at the lowest possible concentration for
safety reasons as well as to minimize the repeated adminis-
tration and cost of treatment, and in light of the excellent
safety track record of PMOs, PMO25 should be considered
for future clinical applications.
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